Comparison between computed tomography‐guided percutaneous microwave ablation and thoracoscopic lobectomy for stage I non‐small cell lung cancer. Issue 11 (28th August 2018)

• Record Type: Journal Article
• Authors: Wang, Yongzheng; Liu, Bin; Cao, Pikun; Wang, Wujie; Wang, Wei; Chang, Haiyang; Li, Dong; Li, Xiao; Zhao, Xiaogang; Li, Yuliang
• Is Part Of: Thoracic cancer. Volume 9:Issue 11(2018)
• Page Start: 1376
• Page End: 1382
• Publication Date: 2018-08-28
• Subjects: Disease free survival -- microwave ablation -- non‐small‐cell lung cancer -- overall survival -- surgery; Chest -- Cancer -- Periodicals; Chest -- Cancer -- Treatment -- Periodicals; Chest -- Surgery -- Periodicals; 616.99494005
• DOI: 10.1111/1759-7714.12842
• Languages: English
• ISSNs: 1759-7706

Abstract

Abstract : Background: The study was conducted to investigate the effectiveness and cost of computed tomography (CT)‐guided percutaneous microwave ablation (MWA) and thoracoscopic lobectomy for stage I non‐small cell lung cancer (NSCLC). Methods: We retrospectively analyzed the data of 46 and 85 patients with stage I NSCLC treated with CT‐guided percutaneous MWA or thoracoscopic lobectomy, respectively, at our center from July 2013 to June 2015. Overall survival (OS), disease‐free survival (DFS), local control rate, hospital stay, and cost were evaluated. Survival curves were constructed using the Kaplan–Meier method and compared using the log‐rank test. Results: The one and two‐year OS rates were 97.82% and 91.30% and 97.65% and 90.59% in the MWA and lobectomy groups, respectively. The one and two‐year DFS rates were 95.65% and 76.09% and 95.29% and 75.29%, respectively. No significant differences were observed in log‐rank analysis between the groups ( P = 0.169). The hospital stays in the MWA and lobectomy groups were 6.62 ± 2.31 and 9.57 ± 3.19 days, respectively. The costs of MWA and lobectomy were US$3274.50 ± US$233.91 and US$4678.87 ± US$155.96, respectively. The differences were all significant ( P = 0.003). Conclusion: MWA and thoracoscopic lobectomy for stage I NSCLC demonstrate similar one and two‐year OS and DFS, with no significant differences between the two groups. MWA involved a shorter hospital stay and lower cost, thus should be considered a better option for patients with severe cardiopulmonary comorbidity and patients unwilling to undergo surgery.